Prot# TMC125-C223: A Randomized, Controlled, Partially Blinded Phase IIb Dose-Finding Trial of TMC125, in HIV-1 Infected Subjects with Documented Genotypic Evidence of Resistance to Currently Available NNRTIs and With at Least Three Primary PI Mutations

Project: Research project

Project Details

StatusFinished
Effective start/end date7/20/04 → 8/8/07

Funding

  • PPD Development (TMC125-C223)
  • Tibotec Pharmaceuticals Ltd. (TMC125-C223)